The Melatonin Price in North America demonstrated a declining trend during Q3 of 2022. The "zero-covid tolerance" policy imposed in China, a significant supplier, severely restricted the export of a range of Active Pharmaceutical Ingredients (APIs), including Melatonin, in the US during the past few months. However, the domestic market had enough inventories to meet the domestic demand from the end-user sectors throughout the first half of the quarter. Numerous production facilities in China were forced to close during H2 of Q3 due to the heat wave and power deficit, and several nutraceutical manufacturing sites were under maintenance, which negatively affected the US trade. A number of businesses and industries blamed a variety of factors for the drop in demand in the US, including the lingering impacts of spiking inflation, supply constraints, rising interest rates, and heightened uncertainty about the outlook for the economy.

For more information
E-Mail:- sales@chemanalyst.com
websites:- https://www.chemanalyst.com/Pricing-data/melatonin-1226
Contact No:- +13322586602